#Moderna

Today in AI: mRNA Cancer Vaccine Clears Phase 3

Moderna and Merck said their personalized mRNA cancer vaccine hit phase 3 endpoints in melanoma, the first success after 1,000 failures.

Moderna-Merck Melanoma Vaccine Shows Promising Results

Moderna and Merck have announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, demonstrating a significant reduction in melanoma recurrence. This development marks a major step forward in cancer treatment.

Moderna Stock Drops Amidst Legal Settlement and Guidance Cuts

Moderna's stock fell 10% following a $955 million legal settlement and a revised, lower sales forecast, while Bristol Myers Squibb saw gains.

GPT-5 Ignites Moderna's Second Computing Revolution